JACI: Phase II clinical trial led by Chinese scientists shows that Rousotani can be effective in promoting recovery in patients with severe new coronary pneumonia

June 3, 2020 /PRNewswireBIOON/--- a genetically modified mouse developed by Cincinnati Children's Hospital to simulate the deadly childhood immune disease HLH (hemophagotic lymphophoitstosis, haemophilocellular lymphocytosis) may play a key role in saving lives during the COVID-19 pandemicDrGang Huang, a cancer pathologist at Cincinnati Children's Hospital,one of the inventors of this genetically engineered mouse species------ co-author of a small Phase II clinical trialThe clinical trial was led by researchers from Tongji Medical College, Wuhan First Hospital and Zhongnan University in ChinaIn thisclinical trialthey successfully tested a drug used to treat HLH--- ruxolitinib, which showed that the drug significantly reversed respiratory and multi-system inflammation in patients with severe COVID-19The results of the clinical study, published online May 26, 2020 in the journal of Allergy and Clinical Immunology, are titled "Ruxolitinib ibib in in-treatment of severe coronavirus disease 2019 (COVID-19): Acenter, multi-blind, randomized trial trial."images from Journal of Allergy and Clinical Immunology, 2020, doi:10.1016/j.jaci.2020.05.019this clinical study involved 43 hospitalized patients diagnosed with severe COVID-19 in Wuhan, China, between February 9 and February 28The multi-center clinical study was led by Professor Jianfeng Zhou of the Department of Blood at Tongji Hospital, affiliated with Tongji Medical College, Huazhong University of Science and TechnologyProfessor Zhou Jianfeng is a long-term collaborator of DrHuang and his colleagues at the HLH Center of Excellence at Cincinnati Children's HospitalRussotini showed signs of benefit
randomly selected patients taking Rousotini twice daily to take the anti-inflammatory drug, taking 5 mg each time, plus COVID-19 standard care therapy A randomly selected control group of 21 patients received placebo and standard care therapy "Numerically, Russotini users showed faster clinical improvement," the authors wrote Significant improvements in chest CT, faster recovery of lymphocytes, and good side effects are encouraging, which provides information for future clinical trials to test the efficacy of rusotinib in larger populations "
the median clinical improvement time in patients treated with Rousotinib was shorter than in the control group The authors reported that 90 percent of patients treated with Russotini showed chest CT improvement sourwith lying within 14 days, compared with 9 percent in the control group Three patients in the control group eventually died of respiratory failure All seriously ill patients treated with Russotini survived need to use the drug for more clinical trials According to Huang, a larger Phase III clinical trial conducted by Incyte and Novartis RUXCOVID is currently testing up to 400 patients with severe COVID-19 He added that preliminary clinical data on the clinical study are expected to be available this summer "This is the first drug we know that appears to be effective in suppressing cytokine storms and inflammation in patients with COVID-19 severe illness, and there is no significant toxicity in patients who take this drug every day," Huang said This is critical until we can develop and distribute a vaccine that is effective enough to help prevent people from became infected "
inhibit "cytokine storms" so-called cytokine storms flood the immune system's inflammatory cells in patients with severe COVID-19, a common feature in children who struggle with secondary HLH, which occurs in patients who struck ineffective treatment with the initial HLH Scientists have been working on research and finding treatments for COVID-19, noting the common clinical characteristics of both diseases Huang also noted that the clinical manifestations of severe COVID-19 disease are very similar to those of genetically modified laboratory mice that faithfully mimicthe human secondary HLH in the laboratory Previous preclinical laboratory studies have helped identify the drug Lusotinib, which treats secondary HLH The anti-inflammatory drug is also used to treat other blood disorders, including leukemia "I found a colleague from Wuhan who explained our observations and suggested that clinical trials of the drug be conducted to to suppress cytokine storms in patients with severe COVID-19 multisystemic inflammation," Huang said The disease spread very quickly at the time and many people died We believe that existing clinical drugs can help save lives So we're trying to move it forward before everyone has an effective vaccine Huang said the clinical study he and his Chinese colleagues conducted was done in a very limited time because scientists around the world were on high alert in January to combat the COVID-19 pandemic During the clinical study, Huang and Chinese researchers found that Roussotini also had a good effect on inflammation in clinical studies for other diseases, so patients with COVID-19 were tested for the drug (Bio Valley Bioon.com) References: 1.Yang Cao et al.
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-single-blind, randomized controlledtrial trial Journal of Allergy and Clinical Immunology, 2020, doi:10.1016/j.jaci.2020.05.019.
2 Cincinnati Children's HLH Research Points to Treatment for COVID-19 Cytokine Storms
https://